Analysis of Lithuanian CYP2D6 polymorphism and its relevance to psychiatric care of the local population

References

• Wium-Andersen IK, Vinberg M, Kessing LV. Personalized medicine in psychiatry. Nord J Psychiatry. 2017;71:12–19.
   PubMed Web of Science ®Google Scholar
• Andre K, Kampman O, Illi A. SERT and NET polymorphisms, temperament and antidepressant response. Nord J Psychiatry. 2015;69:531–538.
   PubMed Web of Science ®Google Scholar
• Shah RR, Gaedigk A. Precision medicine: does ethnicity information complement genotype-based prescribing decisions? Ther Adv Drug Saf. 2018;9:45–62.
   PubMed Web of Science ®Google Scholar
• Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry. 2007;18:39–60.
   PubMed Web of Science ®Google Scholar
• Shah RR. Tyrosine kinase inhibitor-induced interstitial lung disease: clinical features, diagnostic challenges, and therapeutic dilemmas. Drug Saf. 2016;39:1073–1091.
   PubMed Web of Science ®Google Scholar
• Ramamoorthy A, Pacanowski MA, Bull J, et al. Racial/ethnic differences in drug disposition and response: review of recently approved drugs. Clin Pharmacol Ther. 2015;97:263–273.
   PubMed Web of Science ®Google Scholar
• Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet. 2009;48:689–723.
   PubMed Web of Science ®Google Scholar
• Lerena A, Dorado P, Peñas LLedó. EM, Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics. 2009;10:17–28.
   PubMed Web of Science ®Google Scholar
• He ZX, Chen XW, Zhou ZW, et al. Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine. Drug Metab Rev. 2015;1–50.
   Web of Science ®Google Scholar
• Gaedigk A, Sangkuhl K, Whirl-Carrillo M, et al. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017;19:69–76.
   PubMed Web of Science ®Google Scholar
• Kalman LV, Agúndez J, Appell ML, et al. Pharmacogenetic allele nomenclature: international workgroup recommendations for test result reporting. Clin Pharmacol Ther. 2016;99:172–185.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6–13.
   PubMed Web of Science ®Google Scholar
• Miksys SL, Tyndale RF. Drug-metabolizing cytochrome P450s in the brain. J Psychiatry Neurosci. 2002;27:406–415.
   PubMed Web of Science ®Google Scholar
• Hiroi T, Imaoka S, Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun. 1998;249:838–843.
   PubMed Web of Science ®Google Scholar
• Yu AM, Idle JR, Byrd LG, et al. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics. 2003;13:173–181.
   PubMedGoogle Scholar
• González I, Peñas-Lledó EM, Pérez B, et al. Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics. 2008;9:833–840.
   PubMed Web of Science ®Google Scholar
• LLerena A, Dorado P, Peñas-LLedó EM, et al. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. Pharmacogenomics J. 2007;7:408–410.
   PubMed Web of Science ®Google Scholar
• Peñas-Lledó EM, Dorado P, Agüera Z, et al. CYP2D6 polymorphism in patients with eating disorders. Pharmacogenomics J. 2012;12:173–175.
   PubMed Web of Science ®Google Scholar
• Peñas-Lledó EM, Dorado P, Agüera Z, et al. High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders. Mol Psychiatry. 2011;16:691–692.
   PubMed Web of Science ®Google Scholar
• Peñas-Lledó EM, Blasco-Fontecilla H, Dorado P, et al. CYP2D6 and the severity of suicide attempts. Pharmacogenomics. 2012;13:179–184.
   PubMed Web of Science ®Google Scholar
• Zackrisson AL, Lindblom B, Ahlner J. High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clin Pharmacol Ther. 2010;88:354–359.
   PubMed Web of Science ®Google Scholar
• McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol. 2012;8:371–382.
   PubMed Web of Science ®Google Scholar
• Barta M. Silence on the endemic suicides in Lithuania: background, causes, and prospective solutions [Honor thesis]. California: Dominican University of California; 2017.
   Google Scholar
• Man M, Farmen M, Dumaual C, et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol. 2010;50:929–940.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Sim SC. Intronic polymorphisms of cytochromes P450. Hum Genomics. 2010;4:402–405.
   PubMedGoogle Scholar
• Penas-Lledo EM, Trejo HD, Dorado P, et al. CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients. Mol Psychiatry. 2013;18:8–9.
   PubMed Web of Science ®Google Scholar
• LLerena A, Berecz R, de la Rubia A, et al. QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy. Eur J Clin Pharmacol. 2002;58:223–224.
   PubMed Web of Science ®Google Scholar
• Brandl EJ, Kennedy JL, Müller DJ. Pharmacogenetics of antipsychotics. Can J Psychiatry. 2014;59:76–88.
   PubMed Web of Science ®Google Scholar
• Lengvenytė A, Strumila R, Dlugauskas E, et al. CYP450 enzymes genetic polymorphism influence on treatment of affective disorders. Eur Psychiatry. 2017;41:S167–S168.
   Web of Science ®Google Scholar
• Montane Jaime LK, Lalla A, Steimer W, et al. Characterization of the CYP2D6 gene locus and metabolic activity in Indo- and Afro-Trinidadians: discovery of novel allelic variants. Pharmacogenomics. 2013;14:261–276.
   PubMed Web of Science ®Google Scholar
• Shen H, He MM, Liu H, et al. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab Dispos. 2007;35:1292–1300.
   PubMed Web of Science ®Google Scholar
• Peñas-LLedó EM, LLerena A. CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials. Br J Clin Pharmacol. 2014;77:673–683.
   PubMed Web of Science ®Google Scholar
• Stingl JC, Viviani R. CYP2D6 in the brain: impact on suicidality. Clin Pharmacol Ther. 2011;89:352–353.
   PubMed Web of Science ®Google Scholar
• Josefsson A, Sydsjö G, Berg G, et al. CYP2D6 genotypes and depressive symptoms during late pregnancy and postpartum. Nord J Psychiatry. 2004;58:61–64.
   PubMed Web of Science ®Google Scholar